Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | BPTF | Q12830 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.42 |
| ▸ | HTR3B | O95264 | 4/20 | 0.42 |
| ▸ | HTR3A | P46098 | 4/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743397 | 0.82 | MAPT (0.40) | ALDH1A1CYP1A2MAPK1HRH4TSHR | |
| SCHEMBL2067822 | 0.82 | MAPT (0.36) | PLD1ALDH1A1KDM4ECYP1A2TSHR | |
| SCHEMBL1316269 | 0.81 | MAPT (0.41) | ALDH1A1CYP1A2HRH4HPGDTSHR | |
| SCHEMBL4778875 | 0.78 | HRH3 (0.37) | HRH3HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL182759 | 0.78 | ALDH1A1 (0.44) | ALDH1A1KDM4EHSD17B10CYP1A2HTT | |
| SCHEMBL932525 | 0.78 | HRH4 (0.45) | HRH3ALDH1A1HTR3EHTR3BHTR3A | |
| SCHEMBL8206425 | 0.78 | CNR2 (0.39) | PLD1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL21815502 | 0.77 | ACVR1 (0.41) | ALDH1A1 | |
| SCHEMBL8199221 | 0.76 | SMPD3 (0.39) | ALDH1A1KDM4EMAPK1HTTSMN1; SMN2 | |
| SCHEMBL4775116 | 0.76 | LMNA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| CN-114761406-B | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-4069693-B1 | HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-20 | — | — | EP | claimed |
| US-20230295109-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | claimed |
| EP-3953356-B1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-07-26 | — | — | EP | claimed |
| CN-116323589-A | Pyridone compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-06-23 | — | — | CN | claimed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| US-20230022297-A1 | HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | claimed |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | claimed |
| CN-114761406-A | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | claimed |
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | claimed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | claimed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| EP-2049502-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | claimed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | claimed |
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | claimed |
| WO-2008012326-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | claimed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | claimed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | claimed |
| WO-2006130673-A1 | 3-BENZOIMIDAZOLYL-PYRAZOLOPYRIDINES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | PRKDC, PRKACA, ABL1 | PLD1 1918/4885HRH3 2483/4885BPTF 3081/4885 |
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | PLD1 3604/4885HRH3 625/4885BPTF 1523/4885 |
| US-20230295109-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | PNPO, PDXK, C5 | PLD1 1920/4885HRH3 15/4885BPTF 2497/4885 |
| US-20230022297-A1 | HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | TLR7, TLR9, TLR5 | PLD1 2379/4885HRH3 14/4885BPTF 1127/4885 |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | PLD1 445/4885HRH3 4562/4885BPTF 2535/4885 |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | PLD1 3677/4885HRH3 599/4885BPTF 1531/4885 |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | PLD1 1762/4885HRH3 782/4885BPTF 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.